Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53

BACKGROUND: Improved mesothelioma patient survival will require development of novel and more effective pharmacological interventions. TP53 genomic mutations are uncommon in mesothelioma, and recent data indicate that p53 remains functional, and therefore is a potential therapeutic target in these c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Wen-Bin, Lu, Minmin, Eilers, Grant, Li, Hailong, Ding, Jiongyan, Meng, Xuli, Wu, Yuehong, He, Quan, Sheng, Qing, Zhou, Hai-Meng, Fletcher, Jonathan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104897/
https://www.ncbi.nlm.nih.gov/pubmed/27736841
http://dx.doi.org/10.1038/bjc.2016.331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104897/
https://www.ncbi.nlm.nih.gov/pubmed/27736841
http://dx.doi.org/10.1038/bjc.2016.331

Ejemplares similares